{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:20Z","timestamp":1794047480199,"version":"4.8.0"},"reference-count":20,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"3","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>This multicenter, open-label, phase Ib study (ACE-LY-106) assessed the safety and efficacy of acalabrutinib, bendamustine, and rituximab (ABR) in treatment-na\u00efve (TN) and relapsed or refractory (R\/R) mantle cell lymphoma (MCL). Patients received acalabrutinib from cycle 1 until disease progression or treatment discontinuation, bendamustine on days 1 and 2 of each cycle for up to 6 cycles, and rituximab on day 1 of each cycle for 6 cycles, continuing every other cycle from cycle 8 for 12 additional doses (TN cohort). Eighteen patients enrolled in the TN cohort and 20 in the R\/R cohort. Median duration of exposure to acalabrutinib was 34.0 and 14.6 months in the TN and R\/R cohorts, respectively. No new safety risks were identified, and most adverse events (AE) were grades 1 or 2. Thirteen patients from the TN cohort (72.2%) and 17 patients from the R\/R cohort (85.0%) reported grade 3-4 AE, most commonly neutropenia (TN: 38.9%; R\/R: 50.0%). AE leading to death were pneumonitis (N=1, TN cohort), COVID-19, and cerebrospinal meningitis (N=1 each, R\/R cohort). Overall response was 94.4% and 85.0% in the TN and R\/R cohorts, respectively; complete response rates were 77.8% and 70.0%, respectively. After a median follow-up of 47.6 months, median progression-free survival (PFS) and overall survival (OS) were not reached in the TN cohort. After a median follow-up of 20.4 months, median PFS was 28.6 months and OS was not reached in the R\/R cohort. Results indicate that ABR was safe and efficacious, supporting further study in patients with TN MCL.<\/jats:p>","DOI":"10.3324\/haematol.2023.284896","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T15:42:10Z","timestamp":1725550930000},"page":"715-724","source":"Crossref","is-referenced-by-count":5,"title":["Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-na\u00efve or relapsed\/refractory mantle cell lymphoma: phase Ib trial"],"prefix":"10.3324","volume":"110","author":[{"given":"Tycel","family":"Phillips","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeusz","family":"Robak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gallinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krish","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safaa","family":"Ramadan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-Chuan","family":"Wun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"key":"73321","doi-asserted-by":"crossref","unstructured":"Dreyling M, Campo E, Hermine O. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(Suppl 4):iv62-iv71.","DOI":"10.1093\/annonc\/mdx223"},{"key":"73322","doi-asserted-by":"crossref","unstructured":"Narkhede M, Goyal G, Shea L, Mehta A, Giri S. Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma. Blood Adv. 2022; 6(14):4122-4131.","DOI":"10.1182\/bloodadvances.2022007247"},{"key":"73323","doi-asserted-by":"crossref","unstructured":"Jain P, Wang ML. Mantle cell lymphoma in 2022--a comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol. 2022; 97(5):638-656.","DOI":"10.1002\/ajh.26523"},{"key":"73324","doi-asserted-by":"crossref","unstructured":"Robak T, Huang H, Jin J. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015; 372(10):944-953.","DOI":"10.1056\/NEJMoa1412096"},{"key":"73325","doi-asserted-by":"crossref","unstructured":"Robak T, Jin J, Pylypenko H. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol. 2018; 19(11):1449-1458.","DOI":"10.1016\/S1470-2045(18)30685-5"},{"key":"73326","doi-asserted-by":"crossref","unstructured":"Eskelund CW, Kolstad A, Jerkeman M. 15-year follow-up of the second Nordic mantle cell lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016; 175(3):410-418.","DOI":"10.1111\/bjh.14241"},{"key":"73327","doi-asserted-by":"crossref","unstructured":"Eyre TA, Cheah CY, Wang ML. Therapeutic options for relapsed \/ refractory mantle cell lymphoma. Blood. 2022; 139(5):666-677.","DOI":"10.1182\/blood.2021013326"},{"key":"73328","doi-asserted-by":"crossref","unstructured":"Podoll T, Pearson PG, Kaptein A. Identification and characterization of ACP-5862, the major circulating active metabolite of acalabrutinib: both are potent and selective covalent Bruton tyrosine kinase inhibitors. . J Pharmacol Exp Ther. 2023; 384(1):173-186.","DOI":"10.1124\/jpet.122.001116"},{"key":"73329","unstructured":"AstraZeneca Pharmaceuticals. Calquence [package insert]. Wilmington, DE. 2024."},{"key":"73330","doi-asserted-by":"crossref","unstructured":"Phillips T, Smith SD, Jurczak W. Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naive (TN) or relapsed\/refractory (R\/R) mantle cell lymphoma (MCL). Clin Lymphoma Myeloma Leuk. 2019; 19(Suppl 1):S317.","DOI":"10.1016\/j.clml.2019.07.293"},{"key":"73331","doi-asserted-by":"crossref","unstructured":"Jain P, Zhao S, Lee HJ. Ibrutinib with rituximab in first-line treatment of older patients with mantle cell lymphoma. J Clin Oncol. 2022; 40(2):202-212.","DOI":"10.1200\/JCO.21.01797"},{"key":"73332","doi-asserted-by":"crossref","unstructured":"Le Gouill S, Morschhauser F, Chiron D. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1\/2 trial. Blood. 2021; 137(7):877-887.","DOI":"10.1182\/blood.2020008727"},{"key":"73333","doi-asserted-by":"crossref","unstructured":"Wang ML, Jurczak W, Jerkeman M. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med. 2022; 386(26):2482-2494.","DOI":"10.1056\/NEJMoa2201817"},{"key":"73334","doi-asserted-by":"crossref","unstructured":"Maddocks K, Christian B, Jaglowski S. A phase 1\/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed\/refractory non-Hodgkin lymphoma. Blood. 2015; 125(2):242-248.","DOI":"10.1182\/blood-2014-08-597914"},{"key":"73335","doi-asserted-by":"crossref","unstructured":"Byrd JC, Harrington B, O\u2019Brien S. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016; 374(4):323-332.","DOI":"10.1056\/NEJMoa1509981"},{"key":"73336","doi-asserted-by":"crossref","unstructured":"Byrd JC, Hillmen P, Ghia P. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia:. results of the first randomized phase 3 trial J Clin Oncol. 2021; 39(31):3441-3452.","DOI":"10.1200\/JCO.21.01210"},{"key":"73337","unstructured":"Wang M, Mayer J, Belada D. Acalabrutinib plus bendamustine and rituximab in untreated mantle cell lymphoma: results from the phase 3, double-blind, placebocontrolled ECHO trial [abstract LB3439]. Annual Congress of the European Hematology Association; June 13-16. 2024."},{"key":"73338","doi-asserted-by":"crossref","unstructured":"Hawkes EA, Fletcher R, Wood A. Traverse: a phase 2, open-label, randomized study of acalabrutinib in combination with venetoclax and rituximab in patients with treatment-naive mantle cell lymphoma. Blood. 2023; 142(Suppl 1):3054.","DOI":"10.1182\/blood-2023-174718"},{"key":"73339","doi-asserted-by":"crossref","unstructured":"Kumar A, Soumerai J, Abramson JS. A multicenter phase 2 trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in patients with treatment-na\u00efve, TP53-mutant mantle cell lymphoma. Blood. 2023; 142(Suppl 1):738.","DOI":"10.1182\/blood-2023-180069"},{"key":"73340","doi-asserted-by":"crossref","unstructured":"Patel DA, Wan F, Trinkaus K. Bendamustine\/rituximab plus cytarabine\/rituximab, with or without acalabrutinib, for the initial treatment of transplant-eligible mantle cell lymphoma patients: pooled data from two pilot studies. Clin Lymphoma Myeloma Leuk. 2023; 23(7):552-560.","DOI":"10.1016\/j.clml.2023.04.003"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284896\/77485","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284896\/78117","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11743\/77485","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:17Z","timestamp":1794046037000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284896","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,5]]}}}